Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.

doi:10.1158/1078-0432.CCR-22-3318

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2023

Liam Chong Kin, Ahmad Azura Rozila, Hsia Te-Chun, Zhou Jianying, Kim Dong-Wan, Soo Ross Andrew, Cheng Ying, Lu Shun, Shin Sang Won, Yang James Chih-Hsin, Zhang Yiping, Zhao Jun, Berghoff Karin, Bruns Rolf, Johne Andreas, Wu Yi-Long

Abstract excerpt

PURPOSE: The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective MET inhibitor) plus gefitinib versus chemotherapy in patients with MET-altered EGFR-mutant NSCLC (data cut-off: September 3, 2021). PATIENTS AND METHODS: Adults with advanced/metastatic EGFR-mutant NSCLC, acquired resistance to first-/second-generation EGFR inhibitors, and MET gene copy number (GCN) ≥5, MET:CEP7 ≥2, or MET...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Disease-Free Survival

Share to ErbB Receptors

Share to Gefitinib

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 36971777
DOI: 10.1158/1078-0432.CCR-22-3318
PMCID: PMC10183805

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.PMID 36971777Read ↗

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.Semantic proximity Read ↗

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.Semantic proximity Read ↗

Efficacy and safety of tepotinib in MET‑altered non‑small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Targeting MET in 2025: From Exon 14 Skipping to MET-Amplified Acquired Resistance in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17).Semantic proximity Read ↗

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification.Semantic proximity Read ↗

Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients.Semantic proximity Read ↗

The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.Semantic proximity Read ↗

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.Semantic proximity Read ↗

Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET RearrangementsSemantic proximity Read ↗

Crizotinib in Patients With MET-Amplified NSCLC.Semantic proximity Read ↗

Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.